Nestle enters agreement to develop ulcerative colitis therapy

ZURICH, Sept 16 (Reuters) - Nestle is working with Lipid Therapeutics to develop and commercialise a new therapeutic treatment for mild-to-moderate ulcerative colitis, which can causes ulcers, bleeding and pain due to inflammation of the colon, the company said on Wednesday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.